Galapagos NV (GLPG) Actualités

Galapagos creates new subscription right plans

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T...

Galapagos reports first quarter 2024 financial results  

Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical...

Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that...

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in...

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

Publication of annual report for financial year 2023Annual Shareholders’ Meeting resolutions include approval...

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Galapagos presents at EBMT-EHA annual meeting 2024

Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the...